NEW YORK (
) -- Merz Pharma Group withdrew its offer for
Obagi Medical Products Inc.,
( OMPI )
which is under a $420 million merger agreement with
Valeant Pharmaceuticals International Inc.,
( VRX )
leaving the Valeant deal presumably to move forward on a fast track.
Acquisitive Valeant, however, pulled and refiled its application for antitrust approval last week, raising some question about whether the Federal Trade Commission wants to probe the transaction further.
Valeant shares slipped 0.4% to $71.80 while Obagi fell 0.1% to $23.95.
Valeant announced a $19.75 per share deal March 20 to acquire Obagi, which has business in the physician-dispensed skin care markets. Merz had failed to make a firm offer before the sale to Valeant was complete and moved in with a $22 per share spoiler bid. Valeant swiftly countered with a $24 per share revised merger.
Merz said Monday it would back down because the price no longer met their economic requirements. Merz said Obagi was an opportunity worth pursuing given its complementary fit with Merz's portfolio of injectables and that it looks forward to exploring other acquisition opportunities that fit its strategy.
Obagi was seen as an opportunity for Germany's Merz to expand its foothold in North America. The company has said it had other acquisition opportunities that could address the same initiative.
Valeant and Obagi refiled applications under the Hart-Scott-Rodino rules after making an initial filing March 25 that would have had an April 9 deadline at the FTC. A filing on the tender offer with the Securities and Exchange Commission on April 5 noted that after discussions with the FTC staff on April 4, Valeant voluntarily withdrew and refiled its application. Obagi said Valeant is of the position that the refiling may facilitate the completion of the FTC's review. The move is a common maneuver by merger parties to reset the clock on the HSR waiting period. Once the waiting period expires, the FTC is obligated to clear the deal or launch a more thorough second request for information.
Since the deal is structured as a tender offer, the HSR initial review period is only 15 days and would expire on April 19. The Obagi tender offer is set to expire April 23. The companies have asked for early termination of the waiting period.